Cargando…
Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer
In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816167/ https://www.ncbi.nlm.nih.gov/pubmed/31660905 http://dx.doi.org/10.1186/s12888-019-2288-z |
_version_ | 1783463329493155840 |
---|---|
author | dos Santos, Rafael Guimarães Bouso, José Carlos Hallak, Jaime E. C. |
author_facet | dos Santos, Rafael Guimarães Bouso, José Carlos Hallak, Jaime E. C. |
author_sort | dos Santos, Rafael Guimarães |
collection | PubMed |
description | In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In this commentary, we expand the information available on the original article by briefly reviewing data from recent placebo-controlled, double-blind, cross-over clinical trials showing evidence that administration of single (or few) doses of LSD and psilocybin was associated with rapid and sustained reductions in depressive and anxiety symptoms in patients with end-stage cancer and other life-threatening diseases (e.g., Bechterew’s disease, Parkinson’s disease, Celiac disease). Since these substances seem to produce rapid and sustained therapeutic effects with single (or few) doses and well tolerated, large-scale, prospective, multi-site studies of end-stage cancer and classical/serotonergic hallucinogens/psychedelics should be performed to improve our understanding of the therapeutic potentials of these drugs and their use on clinical practice. |
format | Online Article Text |
id | pubmed-6816167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68161672019-10-31 Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer dos Santos, Rafael Guimarães Bouso, José Carlos Hallak, Jaime E. C. BMC Psychiatry Commentary In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In this commentary, we expand the information available on the original article by briefly reviewing data from recent placebo-controlled, double-blind, cross-over clinical trials showing evidence that administration of single (or few) doses of LSD and psilocybin was associated with rapid and sustained reductions in depressive and anxiety symptoms in patients with end-stage cancer and other life-threatening diseases (e.g., Bechterew’s disease, Parkinson’s disease, Celiac disease). Since these substances seem to produce rapid and sustained therapeutic effects with single (or few) doses and well tolerated, large-scale, prospective, multi-site studies of end-stage cancer and classical/serotonergic hallucinogens/psychedelics should be performed to improve our understanding of the therapeutic potentials of these drugs and their use on clinical practice. BioMed Central 2019-10-28 /pmc/articles/PMC6816167/ /pubmed/31660905 http://dx.doi.org/10.1186/s12888-019-2288-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary dos Santos, Rafael Guimarães Bouso, José Carlos Hallak, Jaime E. C. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
title | Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
title_full | Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
title_fullStr | Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
title_full_unstemmed | Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
title_short | Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
title_sort | serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816167/ https://www.ncbi.nlm.nih.gov/pubmed/31660905 http://dx.doi.org/10.1186/s12888-019-2288-z |
work_keys_str_mv | AT dossantosrafaelguimaraes serotonergichallucinogenspsychedelicscouldbepromisingtreatmentsfordepressiveandanxietydisordersinendstagecancer AT bousojosecarlos serotonergichallucinogenspsychedelicscouldbepromisingtreatmentsfordepressiveandanxietydisordersinendstagecancer AT hallakjaimeec serotonergichallucinogenspsychedelicscouldbepromisingtreatmentsfordepressiveandanxietydisordersinendstagecancer |